A recent study demonstrated a cross talk between tumor cells and tumor-associated macrophages (TAMs) via SIGLEC1, CCL8, and CSF1, suggesting that the gene signature of TAMs correlated with poor clinical outcomes (13). This evidence concerns the gene SIGLEC1 and neoplasm.